Jasper Therapeutics, Inc.

Contributing Author

Recent Articles by Jasper Therapeutics, Inc.

Nov-10	Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire
Nov-04	Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR GlobeNewswire
Sep-19	Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants JSPR GlobeNewswire
Sep-18	Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants JSPR GlobeNewswire
Aug-27	Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR GlobeNewswire
Aug-13	Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire
Jul-09	Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway JSPR GlobeNewswire
Jul-07	Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria JSPR GlobeNewswire
Jun-14	Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria JSPR GlobeNewswire
Jun-03	Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress JSPR GlobeNewswire
May-14	Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR GlobeNewswire
May-12	Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire